Heron Therapeutics Inc has a consensus price target of $7 based on the ratings of 4 analysts. The high is $10 issued by Evercore ISI Group on March 24, 2023. The low is $5 issued by Needham on May 16, 2024. The 3 most-recent analyst ratings were released by Rodman & Renshaw, Needham, and Needham on June 13, 2024, May 16, 2024, and May 8, 2024, respectively. With an average price target of $5.67 between Rodman & Renshaw, Needham, and Needham, there's an implied 85.19% upside for Heron Therapeutics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
06/13/2024 | Buy Now | 128.76% | Rodman & Renshaw | Brandon Folkes | → $7 | Initiates | → Buy | Get Alert |
05/16/2024 | Buy Now | 63.4% | Needham | Serge Belanger | → $5 | Reiterates | Buy → Buy | Get Alert |
05/08/2024 | Buy Now | 63.4% | Needham | Serge Belanger | → $5 | Reiterates | Buy → Buy | Get Alert |
04/23/2024 | Buy Now | 96.08% | Capital One | Tim Chiang | → $6 | Initiates | → Overweight | Get Alert |
04/11/2024 | Buy Now | 63.4% | Needham | Serge Belanger | → $5 | Reiterates | Buy → Buy | Get Alert |
03/13/2024 | Buy Now | 63.4% | Needham | Serge Belanger | $4 → $5 | Maintains | Buy | Get Alert |
11/15/2023 | Buy Now | 30.72% | Needham | Serge Belanger | $5 → $4 | Maintains | Buy | Get Alert |
08/15/2023 | Buy Now | 63.4% | Needham | Serge Belanger | → $5 | Reiterates | Buy → Buy | Get Alert |
07/25/2023 | Buy Now | 63.4% | Needham | Serge Belanger | $6 → $5 | Maintains | Buy | Get Alert |
05/12/2023 | Buy Now | 96.08% | Needham | Serge Belanger | $7 → $6 | Maintains | Buy | Get Alert |
04/21/2023 | Buy Now | 128.76% | Needham | Serge Belanger | → $7 | Reiterates | → Buy | Get Alert |
03/24/2023 | Buy Now | 226.8% | Evercore ISI Group | Shweta Khajuria | $15 → $10 | Maintains | Outperform | Get Alert |
03/24/2023 | Buy Now | 128.76% | Needham | Serge Belanger | $8 → $7 | Maintains | Buy | Get Alert |
11/09/2022 | Buy Now | 161.44% | Needham | Serge Belanger | $10 → $8 | Maintains | Buy | Get Alert |
06/30/2022 | Buy Now | 226.8% | Needham | Serge Belanger | $14 → $10 | Maintains | Buy | Get Alert |
05/10/2022 | Buy Now | 357.52% | Needham | Serge Belanger | $16 → $14 | Maintains | Buy | Get Alert |
The latest price target for Heron Therapeutics (NASDAQ:HRTX) was reported by Rodman & Renshaw on June 13, 2024. The analyst firm set a price target for $7.00 expecting HRTX to rise to within 12 months (a possible 128.76% upside). 8 analyst firms have reported ratings in the last year.
The latest analyst rating for Heron Therapeutics (NASDAQ:HRTX) was provided by Rodman & Renshaw, and Heron Therapeutics initiated their buy rating.
There is no last upgrade for Heron Therapeutics
There is no last downgrade for Heron Therapeutics.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Heron Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Heron Therapeutics was filed on June 13, 2024 so you should expect the next rating to be made available sometime around June 13, 2025.
While ratings are subjective and will change, the latest Heron Therapeutics (HRTX) rating was a initiated with a price target of $0.00 to $7.00. The current price Heron Therapeutics (HRTX) is trading at is $3.06, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.